16

nanotimes

Companies

Facts

mobiles. In addition to having a long product life span, the switch‘s high operation force protects against accidental operation, making it suitable for steering wheel and other driver-centered applications. Sample shipments will com- mence from March 2010. By using silver contact points the SKPR Series also limits contact resistance to 100mΩ, making it is easier to develop circuit designs for vehicle-mounted devices operated by this product.

http://www.alps.com/products/e/npv_product/100305_ SKPR/SKPR_E.PDF

systems for clean, efficient power and energy ma- nagement, reported financial results for the year ended December 31, 2009. For the year ended De- cember 31, 2009, the Company reported revenues of $4.4 million, down from $5.7 million for 2008. The net loss was $21.9 million, or 21 cents per share, compared to a net loss of $29.3 million, or 34 cents per share, for 2008.

A

The basic and diluted weighted average shares outstanding for the year were 100.2 million, com- pared to 85.9 million reported in 2008. Operating expenses of $27.2 million for 2009 were $8.7 million less than the operating expenses of $35.9 million for 2008. The 2008 results contained several one-time expenses including the settlement expense of $3.6 million with Al Yousuf LLC, the reversal of $2.9 mil-

ltair Nanotechnologies, Inc. (Altairnano, NASDAQ: ALTI), a provider of energy storage

lion in warranty expense and the forgiveness of $1.7 million in notes receivable associated with resolution of the various Phoenix Motor Cars issues. Similarly, 2009 contains the one-time impairment loss on the AlSher assets of $1.3 million. Even adjusting for all of these one-time items, the 2009 operating expen- se reduction from 2008 was $7.6 million, consisting primarily of the elimination of R&D expenditures of $6.6 million as Altair eliminated activities in the former Life Sciences and Performance Materials divisions. In addition, Altair had a reduction in G&A expenses of $1.6 million resulting from a number of different initiatives. The Company‘s cash and cash equivalents decreased by $10.0 million, from $28.1 million at December 31, 2008 to $18.1 million at December 31, 2009.

“We continue to position the company to take advantage of the opportunities we see develo- ping throughout 2010,” said Dr. Terry Copeland, Altairnano‘s president and CEO. “Discussions with potential customers continue to advance and we ex- pect order activity to gain traction in our key market segments. We have begun to build inventory levels in order to move expeditiously once we have these initial firm orders.”

http://www.altairnano.com

motion for a preliminary injunction in the United States District Court for the District of New Jersey

seeking to enjoin Dr. Reddy’s Laboratories, Ltd.

and Dr. Reddy’s Laboratories, Inc. (Dr. Reddy’s) from the commercial distribution of generic versions of Allegra-D®

A

24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) Extended-Release

MRI (NASDAQ: AMRI) announced that it along with Sanofi-Aventis U.S. LLC, has filed a

10-03 :: March 2010